Author:
Bellini Alice,Aramini Beatrice,Stella Franco
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis, principally caused by a prior asbestos exposure. Up to the present, multimodality protocols including surgery with chemotherapy (CT) and/or radiotherapy (RT) represent the therapeutic gold standard for selected patients (epithelial and early-stage MPM). In this context, the aim of surgery is to accomplish the macroscopic complete resection (MCR). There are two main surgical options to obtain MCR—extrapleural pneumonectomy (EPP) and pleurectomy/decortication (PD). The superiority of one surgical approach over the other is still discussed. To date, the decision to carry out one or the other in a multimodal setting is established on surgeons’ preference more than on strong scientific evidence. Due to the high morbidity, both surgical techniques should be achieved in tertiary referral centres. In summary, surgery, CT, and RT have failed as single modality therapies with no effects on patients survival. This aspect may be justified by the lack of randomized trials. Thus, novel therapeutic strategies, such as multimodality treatment and targeted agents, seem to prolong the survival and the quality of life. The aim of this chapter is to provide a complete overview of the current surgical approaches to MPM, discussing within the frameworks of pre-operative diagnostic evaluation and multimodality oncological treatments.
Reference152 articles.
1. National Comprehensive Cancer Network (NCCN). Malignant Pleural Mesothelioma Guidelines Version 2.2021—February 16, 2021 [Internet]. 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf [Accessed: November 01, 2021]
2. Bueno R, Stawiski EW, Goldstein LD. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature Genetics. 2016;48:407-416. DOI: 0.1038/ng.3520
3. Yap TA, Aerts JG, Popat S. Novel insights into mesothelioma biology and implications for therapy. Nature Reviews Cancer. 2017;17:475-488. DOI: 10.1038/nrc.2017.42
4. Scherpereel A, Wallyn F, Albelda S. Novel medical therapies for malignant pleural mesothelioma: A review. The Lancet Oncology. 2018;19:e161-e172. DOI: 10.1016/S1470-2045(18)30100-1
5. Woolhouse I, Bishop L, Darlison L. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(Suppl.1):i1-i30. DOI: 10.1136/thoraxjnl-2017-211321